UK financial authority doing all it ‘reasonably’ can to avoid Brexit market disruption

Globe Newswire

Outlook on the Respiratory Infection Diagnostic Industry to 2025 with COVID-19 Impact

Dublin, Nov. 12, 2020 (GLOBE NEWSWIRE) — The “Respiratory Infection Diagnostic Markets by Technology, Plex, Place and by Region with COVID-19 Impact & Forecasting/Analysis, and Executive and Consultant Guides 2021-2025” report has been added to’s offering. COVID-19 has broken open the market for point of care testing of respiratory infections. Now the competition for market share begins in earnest. Large new markets are opening up. In health facilities, clinics, physicians’ offices and elsewhere. And let’s not forget the screening market, not just for COVID, but for the rest of the 20 something respiratory pathogens as well. Multiplex vs single plex? Explore the rapidly changing market as competitors jockey for position in new markets that are not yet well understood. New technology is forever changing the diagnosis of respiratory infections. Shrinking time to result is opening up markets multiple times the size of current microbiology based practice. Diagnosis has already moved into the Emergency Room. It is now moving to the Physician’s Office Lab. Could the Home be next? The Multiplex factor is creating market confusion while lowering costs and improving care but important factors are holding back progress. The widespread nature of respiratory infections, (young people can get 8 colds a year) means that potential market sizes are enormous. Respiratory, already the largest infectious disease category could multiply in size. This is a growth opportunity for all diagnostic companies. Understand the opportunity and the risk with this in-depth report. Respiratory Infections Diagnostic Market – Strategic Situation Analysis and Impact of COVID-19 Guide for Executives, Marketing, Sales and Business Development StaffGuide for Management Consultants and Investment Advisors Key Topics Covered: 1. Introduction and Market Definition 1.1 What are Respiratory Infections? 1.2 The Role of Diagnosis & Treatment1.3 Market Definition 1.3.1 Revenue Market Size1.4 Methodology 1.4.1 Authors 1.4.2 Sources 1.5 A Spending Perspective on Clinical Laboratory Testing 1.5.1 An Historical Look at Clinical Testing 2. Market Overview 2.1 Players in a Dynamic Market 2.1.1 Academic Research Lab 2.1.2 Diagnostic Test Developer2.1.3 Instrumentation Supplier 2.1.4 Distributor and Reagent Supplier 2.1.5 Independent Testing Lab2.1.6 Public National/regional lab 2.1.7 Hospital lab 2.1.8 Physician Office Labs 2.1.9 Audit Body 2.1.10 Certification Body2.2 Respiratory Infections 2.2.1 Upper vs. Lower – Marketing Implications2.2.2 Understanding the Role of Pneumonia 2.2.3 Bacterial Infections2.2.3.1 Streptococcal Infections Acute Otitis Media Bacterial Rhinosinusitis Diphtheria Pneumococcal Pneumonia Haemophilus Pneumonia Mycoplasma Pneumonia (Walking Pneumonia) Chlamydial Pneumonias and Psittacosis2.2.3.9 Health Care-Associated Pneumonia2.2.3.10 Pseudomonas Pneumonia Pertussis (Whooping Cough) Legionnaires Disease2.2.4 Tuberculosis – A Special Case 2.2.5 Viral Infections The Common Cold Influenza Viral Pneumonia SARS and MERS Measles (Rubeola) Rubella (German Measles) Chickenpox and Shingles 2.2.6 Fungal and Other Pathogens Histoplasmosis Coccidioidomycosis2.2.6.3 Blastomycosis Mucormycosis2.2.6.5 Aspergillosis Pneumocystis Pneumonia Cryptococcosis 2.3 Diagnostics – A Changing Role 2.3.1 Historical Practice2.3.2 Current Diagnostics 2.3.3 The Multiplex Vector 2.3.4 Future Diagnostics – The Question of When and Where 2.3.5 Respiratory Infection Diagnostics – The Destination 2.3.6 Diagnostics as Defensive Weapons 2.4 COVID-19 2.4.1 Signs and symptoms 2.4.2 Transmission2.4.3 Diagnosis 2.4.4 Prevention 2.4.5 Management 2.4.6 Prognosis 2.5 Pandemic Diagnostics 2.5.1 Risk Management – Spark and Spread 2.5.2 Dx Technology – Nucleic Acid Based2.5.3 Dx Technology – Immunoassay & Serology 2.5.4 Time to Market and Preparedness Issues 2.5.5 Unrecognized Role of Multiplex in Pandemic Management 3. Market Trends3.1 Factors Driving Growth 3.1.1 Syndromic Multiplexing 3.1.2 T.A.T3.1.3 Antimicrobial Resistance Movement3.1.4 Pandemic Mitigation 3.1.5 An Aging at Risk Population 3.2 Factors Limiting Growth3.2.1 The Cost Curve 3.2.2 Regulation and coverage 3.2.3 Laissez Faire 3.3 Instrumentation and Automation3.3.1 The Shrinking Multiplexing Machine 3.3.2 Bioinformatics Networking and Anonymous Reporting 3.4 Diagnostic Technology Development3.4.1 The Key Role of Time to Result 3.4.2 Single Cell Genomics Changes the Picture 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment 3.4.4 Pathogen Identification – A Projected Timetable of the Future 4. Respiratory Infection Diagnostics Recent Developments 4.1 Recent Developments – Importance and How to Use This Section 4.1.1 Importance of These Developments 4.1.2 How to Use This Section GenMark to Meet Pent Up Demand for SARS-CoV-2, Respiratory PanelTempus Announces Large-Scale COVID-19 Testing, Data InitiativeAbacus Diagnostica Readying Multiplex Respiratory TestQiagen Acquires NeuMoDx MolecularDx Companies Shift Attention to Multiplex Tests for SARS-CoV-2, InfluenzaNovacyt Gets CE Mark for Coronavirus, Flu, RSV Combo PanelCepheid Debuts 10-Color Technology With New Tuberculosis TestBioMerieux’s Pneumonia Panel Could Improve CareMammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 DiagnosticGenetic Signatures Gets CE Mark for Coronavirus Molecular TestQiagen Respiratory Panel with Coronavirus Receives CE MarkLumos Diagnostics Closes $15M Series A FundingFusion Genomics Wins $1M to Assess NGS-Based Respiratory Tract Infection AssayCoronavirus Detection Test Development by Co-DiagnosticsRapid Diagnostics Completes Asset Purchase of Enigma DiagnosticsFlu-Like Epidemic Could Kill 80 Mn GloballyStartup developing AI for TB detectionNipah Virus a Global ThreatNovacyt S.A.: New Molecular Respiratory Panel Ready for US MarketNew DRC Ebola cases confirmed as FDA OKs rapid testCE Mark for Smartphone-based Diagnostic Test for Adult Respiratory DiseaseCuretis Submits Lower Respiratory Tract Infection Test for FDA ClearanceNew rapid test diagnoses pneumonia and other lower respiratory infectionsOntera Awarded Contract for Zika Genotyping TestTwo New Members Join Global Diagnostics NetworkBARDA Funding Health Security Solutions 5. Profiles of Key Players Abacus DiagnosticaAbbott DiagnosticsAccelerate DiagnosticsAdor DiagnosticsAkkoni BiosystemsAlveo TechnologiesApplied BioCodeAtlas GeneticsAus DiagnosticsBD DiagnosticsBiocartisBioFire DiagnosticsbioMerieuxBio-Rad LaboratoriesBosch Healthcare Solutions GmbHCepheidCo-DiagnosticsCue HealthCuretisDiagenode DiagnosticsDiascopicDiasorinExpedeonFusion GenomicsGenePOC DiagnosticsGenetic SignaturesGenMark DxHologicImmunexpressInflammatixInvetechJanssen DiagnosticsKariusLexigeneLuminexLumos DiagnosticsMammoth BiosciencesMbio DiagnosticsMeridian BioscienceMesa BiotechMobidiagNanomixOxford NanoporePanagenePrimerdesignProminexQiagen (Statdx)QuantumdxQuidelRoche Molecular DiagnosticsSaw DiagnosticsSeegeneSensovationSiemens Healthineers (Fast Track Diagnostics)SkylineDxSona NanotechT2 BiosystemsThermo FisherVeradus LabsVeramarx 6. The Global Market for Respiratory Infection Diagnostics 6.1 Global Market Overview by Country6.1.1 Table – Global Market by Country6.1.2 Chart – Global Market by Country 6.2 Global Market by Technology – Overview 6.2.1 Table – Global Market by Technology 6.2.2 Chart – Global Market by Technology – Base/End Year Comparison6.2.3 Chart – Global Market by Technology – Base Year 6.2.4 Chart – Global Market by Technology – End Year 6.2.5 Chart – Global Market by Technology – Share by Year6.3 Global Market by Plex – Overview 6.3.1 Table – Global Market by Plex 6.3.2 Chart – Global Market by Plex – Base/End Year Comparison 6.3.3 Chart – Global Market by Plex – Base Year 6.3.4 Chart – Global Market by Plex – End Year 6.3.5 Chart – Global Market by Plex – Share by Year6.4 Global Market by Place – Overview 6.4.1 Table – Global Market by Place 6.4.2 Chart – Global Market by Place – Base/End Year Comparison 6.4.3 Chart – Global Market by Place – Base Year 6.4.4 Chart – Global Market by Place – End Year 6.4.5 Chart – Global Market by Place – Share by Year 7. Global Respiratory Infection Diagnostic Markets – By Technology 7.1 Microbiology 7.1.1 Table Microbiology – by Country 7.1.2 Chart – Microbiology Growth 7.2 PCR 7.2.1 Table PCR – by Country 7.2.2 Chart – PCR Growth7.3 NGS7.3.1 Table NGS – by Country7.3.2 Chart – NGS Growth 7.4 Immunoassay/Other7.4.1 Table Immunoassay – by Country 7.4.2 Chart – Immunoassay/Other Growth 7.5 C19 Singleplex 7.5.1 Table C19splex – by Country 7.5.2 Chart – C19splex Growth 8. Global Respiratory Infection Diagnostic Markets – by Plex 8.1 C19 Single Plex8.1.1 Table C19 Single Plex – by Country8.1.2 Chart – C19 Single Plex Growth8.2 Singleplex 8.2.1 Table Singleplex – by Country 8.2.2 Chart – Singleplex Growth8.3 Duplex/Triplex 8.3.1 Table Duplex/Triplex – by Country 8.3.2 Chart – Duplex/Triplex Growth 8.4 Multiplex Technology 8.4.1 Table Multiplex – by Country 8.4.2 Chart – Multiplex Growth 9. Global Respiratory Infection Diagnostic Markets – by Place 9.1 Hospital Lab 9.1.1 Table Hospital Lab – by Country 9.1.2 Chart – Hospital Lab Growth 9.2 Outpatient Lab 9.2.1 Table Outpatient Lab – by Country 9.2.2 Chart – Outpatient Lab Growth 9.3 POC 9.3.1 Table POC – by Country 9.3.2 Chart – POC Growth9.4 Other Technology9.4.1 Table Other – by Country 9.4.2 Chart – Other Growth For more information about this report visit Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT:
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Source link

Add a Comment